BridgeMD
The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)
EU CTIS ID: 2024-511325-67-00
What this study is testing
To determine investigational agents or combinations of agents that reduce the rate of eGFR decline (slow progression of CKD), compared to placebo, in patients with chronic kidney disease receiving standard of care therapy.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Age ≥ 18 years
- 2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m^2)
- 3. Currently receiving standard of care treatment according to treating physician
- 4. Eligible for randomisation in at least one recruiting domain-specific appendix
- 5. Participant and treating physician are willing and able to perform trial procedures
- 6. Urine albumin-creatinine ratio (uACR) >200 mg/g or urine protein-creatinine ratio (uPCR) >300 mg/g from the most recent result in the previous 3 months.
You likely can't join if
- 1. Currently receiving maintenance dialysis
- 10. Severe hepatic impairment (defined as Child-Pugh Class C)
- 11. Adrenal insufficiency
- 12. Currently pregnant or breast feeding, or intending to become pregnant
- 2. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
- 3. Life expectancy less than 6 months
See the full eligibility criteria
- 1. Age ≥ 18 years
- 2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m^2)
- 3. Currently receiving standard of care treatment according to treating physician
- 4. Eligible for randomisation in at least one recruiting domain-specific appendix
- 5. Participant and treating physician are willing and able to perform trial procedures
- 6. Urine albumin-creatinine ratio (uACR) >200 mg/g or urine protein-creatinine ratio (uPCR) >300 mg/g from the most recent result in the previous 3 months.
- 7. On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening according to treating physician.
- 8. Treating physician believes finerenone is clinically appropriate for the participant.
- 9. Participant and treating physician are willing and able to perform Mineralocorticoid Receptor Antagonist Domain-Specific Appendix procedures.
- 1. Currently receiving maintenance dialysis
- 10. Severe hepatic impairment (defined as Child-Pugh Class C)
- 11. Adrenal insufficiency
- 12. Currently pregnant or breast feeding, or intending to become pregnant
- 2. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
- 3. Life expectancy less than 6 months
- 4. Recipient of kidney transplant
- 5. Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
- 6. Current treatment with mineralocorticoid receptor antagonist (MRA), where the treating physician or patient is not willing to discontinue this medication
- 7. Known allergy, intolerance or contraindication to MRAs
- 8. Current treatment with strong CYP3A4 inhibitors
- 9. Systolic BP <110 mmHg or diastolic BP <55 mmHg without antihypertensive therapy at time of screening
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- New Zealand
- India
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; New Zealand; India. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.